Teplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved by the Food and Drug Administration to delay the onset of clinical type 1 diabetes (stage 3) in patients 8 years of age or ...
Janus kinase (JAK) inhibitors, including baricitinib, block cytokine signaling and are effective disease-modifying treatments for several autoimmune diseases. Whether baricitinib preserves β-cell ...
The findings confirm the results of the CNIC-led REBOOT clinical trial and consolidate a paradigm shift in infarction treatment. A major analysis led by the Centro Nacional de Investigaciones ...
A major analysis led by the Centro Nacional de Investigaciones Cardiovasculares (CNIC), in collaboration with international institutions, has pooled data from 17,801 myocardial infarction survivors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results